Vaccinex (VCNX) News Today → Crypto Millionaire Says: “Buy This $11 AI Coin.” (From InvestorPlace) (Ad) Free VCNX Stock Alerts $5.56 -0.19 (-3.30%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 6:40 AM | americanbankingnews.comVaccinex, Inc. (NASDAQ:VCNX) Sees Significant Decrease in Short InterestApril 14, 2024 | investing.comVaccinex faces Nasdaq compliance challengeApril 2, 2024 | investorplace.comVCNX Stock Earnings: Vaccinex Reported Results for Q4 2023April 2, 2024 | globenewswire.comVaccinex Reports 2023 Financial Results and Provides Corporate UpdateMarch 27, 2024 | globenewswire.comVaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesMarch 6, 2024 | investing.comVaccinex CFO Scott Royer to retire, Jill Sanchez steps inMarch 2, 2024 | morningstar.comVaccinex Inc VCNXFebruary 21, 2024 | finanznachrichten.deVaccinex, Inc.: Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus TechnologyFebruary 21, 2024 | markets.businessinsider.comVaccinex Enters Antibody Discovery Agreements Incorporating ActivMAb Drug Discovery PlatformFebruary 21, 2024 | finance.yahoo.comVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus TechnologyFebruary 21, 2024 | globenewswire.comVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus TechnologyFebruary 19, 2024 | marketbeat.comTrading was temporarily halted for "VCNX" at 07:02 PM with a stated reason of "News pending."February 15, 2024 | markets.businessinsider.comVaccinex Announces 1-For-14 Reverse Stock SplitFebruary 15, 2024 | msn.comWhy Vaccinex (VCNX) Stock Is Trading LowerFebruary 15, 2024 | globenewswire.comVaccinex, Inc. Announces Reverse Stock SplitFebruary 12, 2024 | finance.yahoo.comSteven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex IncFebruary 8, 2024 | msn.comVaccinex Inc Secures $3.7M in Private Placement DealFebruary 7, 2024 | msn.comWhy Vaccinex (VCNX) Stock Is Popping OffFebruary 7, 2024 | markets.businessinsider.comVaccinex Announces Pricing of $3.7 Million PIPE FinancingDecember 4, 2023 | finance.yahoo.comNasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing RuleNovember 13, 2023 | finance.yahoo.comVaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 31, 2023 | finance.yahoo.comVaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual MeetingOctober 26, 2023 | finance.yahoo.comVaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative DiseasesOctober 6, 2023 | markets.businessinsider.comWhy Is Vaccinex (VCNX) Stock Up 26% Today?September 29, 2023 | finanznachrichten.deVaccinex, Inc.: Vaccinex Announces Pricing of $9.6 Million Public OfferingSeptember 29, 2023 | marketwatch.comVaccinex Shares Slide Premarket After Stock OfferingSeptember 29, 2023 | finance.yahoo.comVaccinex Announces Pricing of $9.6 Million Public OfferingSeptember 28, 2023 | stockhouse.comVaccinex's Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept CollaborationSeptember 28, 2023 | finance.yahoo.comVaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept CollaborationSeptember 27, 2023 | finance.yahoo.comVaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® ApplicationSeptember 26, 2023 | benzinga.comVaccinex Recent Insider ActivitySeptember 22, 2023 | marketwatch.comVaccinex Board to Implement 1-for-15 Reverse Stock SplitSeptember 22, 2023 | finance.yahoo.comVaccinex, Inc. Announces Reverse Stock SplitAugust 14, 2023 | finance.yahoo.comVaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJune 1, 2023 | finance.yahoo.comVaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ETMay 31, 2023 | benzinga.comVaccinex Stock (NASDAQ:VCNX), DividendsMay 17, 2023 | seekingalpha.comVaccinex GAAP EPS of -$0.10, revenue of $0.55MMay 16, 2023 | finanznachrichten.deVaccinex, Inc.: Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate UpdateApril 25, 2023 | finance.yahoo.comVaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of PepinemabApril 12, 2023 | finance.yahoo.comVaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian CellsApril 3, 2023 | finance.yahoo.comVaccinex Announces Private Placement with Commitments of $5.0 MillionApril 3, 2023 | finance.yahoo.comVaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical ProgramsMarch 23, 2023 | finance.yahoo.comVaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity ConferenceMarch 21, 2023 | finance.yahoo.comVaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)March 9, 2023 | finance.yahoo.comVaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim AnalysisFebruary 11, 2023 | marketbeat.comMarketBeat Week in Review – 2/6 - 2/10 (VCNX)Markets are closed the week looking for direction as investors believe a soft landing is not possible and higher interest rates are likelyFebruary 7, 2023 | marketbeat.comShould Investors Buy or Sell the Vaccinex Patent News?Shares of Vaccinex, Inc. are higher on February 7 on news that the clinical-stage biotechnology company secured a patent. Is it time to buy or sell the news?January 9, 2023 | finance.yahoo.comVaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface OncologyDecember 31, 2022 | finance.yahoo.comVaccinex, Inc. (VCNX) Stock Historical Prices & Data - Yahoo FinanceNovember 28, 2022 | finance.yahoo.comVaccinex Announces $3.8 Million Private Placement Get Vaccinex News Delivered to You Automatically Sign up to receive the latest news and ratings for VCNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto Millionaire Says: “Buy This $11 AI Coin.” (Ad)Right now, you can harness the power of two bull markets... Artificial intelligence...And cryptos. Find out more about this $11 AI Coin right now VCNX Media Mentions By Week VCNX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VCNX News Sentiment▼1.430.57▲Average Medical News Sentiment VCNX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VCNX Articles This Week▼20▲VCNX Articles Average Week Get Vaccinex News Delivered to You Automatically Sign up to receive the latest news and ratings for VCNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: EFTR News Today HEPA News Today CYCN News Today UPC News Today KTTA News Today CANF News Today BNOX News Today VIRI News Today CVKD News Today PCSA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VCNX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersGuard Against the Coming Financial UpheavalPorter & CompanyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsElon’s New Device is About to Shock the WorldInvestorPlaceCharles Payne Demystifies OptionsUnstoppable ProsperityNot Trump. Not Biden. But ___________.The Freeport SocietyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccinex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
